6 shows extension rates as a function of activation time at 95[degrees]C for heat-activated nucleotide analogs (CleanAmp dNTPs) and 2 chemical hot start polymerases (FastStart and Amplitaq Gold).
Rates were faster for the heat-activated nucleotide analogs at all activation times, indicating a large difference in the specific activity of chemically modified hot start polymerases and Klentaq I.
Adefovir and other acyclic nucleotide analogs, such as cidofovir and tenofovir, are substrates for human renal organic anion transporter 1 (hOAT1).
Tenofovir disoproxil fumarate (Viread[R], Gilead Sciences) is a nucleotide analog that has activity against HIV and HBV, and is approved for the treatment of HIV infection and chronic hepatitis B.
Candidates with novel properties are in development in the two major drug classes: HIV reverse transcriptase inhibitors (nucleoside and nucleotide analog
reverse transcriptase inhibitors; non-nucleoside reverse transcriptase inhibitors) and HIV protease inhibitors.
Preliminary data suggest that this nucleotide analog
, also known as PMPA, retains potency against multidrug-resistant viruses.
For platelets from both lean and obese study participants, we investigated (a) sensitivity to the antiaggregatory effects of the cyclic nucleotide analogs 8-pCPT-cAMP and 8-pCPT-cGMP on ADP-induced platelet aggregation; (b) PKA and PKG concentrations; and (c) concentrations of total VASP and of VASP phosphorylation in response to 8-pCPT-cAMP and 8-pCPT-cGMP.
50]) values of the 2 cyclic nucleotide analogs were determined at the different incubation times, when possible.
The study, now appearing in the on-line edition of Nature Methods, demonstrates the synthesis and use of novel, fluorescently labeled, reversible terminator nucleotide analogs
for use in single molecule DNA sequencing.
TABLE 11 NUCLEOTIDE ANALOGS
USED TO TREAT HEPATITIS 37
The proprietary nucleotide analogs
contained in these unique formulations control accurate base-by-base extension through chemical means.
PerkinElmer is the world's leading provider of nucleotide analogs
(in conjunction with Enzo Diagnostics), and offers the broadest selection of nonrad-labeled nucleotides.
The patents allowed relate to fluorescent nucleotide analogs
and establish Chromagen's claims to 1) composition of matter for the fluorescent nucleotide analogs
and 2) the uses of these fluorescent analogs to create internally and end labeled DNA and RNA probes for research, diagnostic and therapeutic purposes.